External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies
Abstract Background Prostate-specific membrane antigen (PSMA)-targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiatio...
Main Authors: | J. Kurth, B. J. Krause, S. M. Schwarzenböck, L. Stegger, M. Schäfers, K. Rahbar |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-04-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13550-018-0386-4 |
Similar Items
-
Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
by: Else A. Aalbersberg, et al.
Published: (2022-09-01) -
Improved quality control of [177Lu]Lu-PSMA I&T
by: Martin Kraihammer, et al.
Published: (2023-03-01) -
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
by: Dagmar Grob, et al.
Published: (2024-04-01) -
Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand [177Lu]Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01) -
Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)